Our findings strengthen the evidence for a tight control of glucose transport in glioblastoma and suggest that combinations of drugs acting on GLUT/SLC2A [83] or interfering with their trafficking may be effective for glioblastoma treatment. Here, SLC2A1 is linked to glioblastoma.